Category Archives: Pre-grant opposition

The role of intellectual property in local production in developing countries: Opportunities and challenges

Source: World Health Organization Intellectual property plays an important role both for the researching pharmaceutical industry, which relies heavily on intellectual property to protect its products, and for generic companies, which produce copies of existing medicines once patent protection expires. … Continue reading

Posted in IPR policy, Patents, Pre-grant opposition, TRIPS, Uncategorized | Leave a comment

Petition to the Malaysian Minister of Health: Make Sofosbuvir available, fix patent laws!

Hepatitis C patients in Malaysia urgently need access to affordable Sofosbuvir. Help them by signing this petition to the Health Minister of Malaysia in the run-up to the International Harm Reduction Conference in Kuala Lumpur.

Posted in Compulsory Licensing, Evergreening, Hepatitis C, IPR policy, Patent Term Extension, Petitions, Post-grant opposition, Pre-grant opposition, Sofosbuvir, US - Malaysia FTA | Leave a comment

Gilead’s local alliances on Hepatitis C drug Sovaldi set for a rough ride

MUMBAI, SEPT 15:   Source: The Hindu California-based Gilead is set to stir the pot as it forges India-based alliances on its Hepatitis C drug sofosbuvir. Multi-company agreements on the drug are expected to be announced later today. Never before has … Continue reading

Posted in Evergreening, Patents, Pre-grant opposition, Pricing, Voluntary License | Tagged , , | Leave a comment

Gilead’s estimated price for Sofosbuvir in India – 2000$

Gilead, local generic players in talks to bring hepatitis C drug into India PT JYOTHI DATTA Source:Hindu Business Line Price to be pegged lower than the current standard of care, estimated at $2,500 for six months MUMBAI, FEBRUARY 3: California-based … Continue reading

Posted in Clinical Trials, Pre-grant opposition, Sofosbuvir, Voluntary License | Leave a comment

Press Release: Trade and Industry’s draft IP policy lays foundation to prevent abusive patents from blocking access to affordable medicines

Health groups call for wide public consultation Johannesburg, 9 September – The Treatment Action Campaign (TAC), Doctors Without Borders (MSF) and SECTION27 welcome the announcement that the Department of Trade and Industry (DTI) has called for public comment on the … Continue reading

Posted in BRICS, Compulsory Licensing, Generics, IP Rights, Post-grant opposition, Pre-grant opposition, Pricing, Right to Health, TRIPS, WHO, WTO | Tagged , , | Leave a comment